Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Faculty Members have conducted research related to the A Cost-Effectiveness Analysis of Risk-Based Intervention for Prevention of Cardiovascular Diseases in Irapen Program: A Modeling Study
Rajabali Daroudi
Rajabali Daroudi

Associate Professor of Health Economics

Department

School of Public Health

Tehran University of Medical Sciences

Related Documents
1. A Cost-Effectiveness Analysis of Risk-Based Intervention for Prevention of Cardiovascular Diseases in Irapen Program: A Modeling Study, Frontiers in Public Health (2023)
2. Cost-Benefit Analysis of Stroke Rehabilitation in Iran, Expert Review of Pharmacoeconomics and Outcomes Research (2023)
All Documents
1. Assessing Health Determinants Worldwide: Econometric Analysis of the Global Burden of Diseases Study 2000-18 - Highlighting Impactful Factors on Daly, Yll, and Yld Indicators, Journal of Global Health (2024)
2. Burden of Ischemic Heart Disease in the Middle East and North Africa (Mena) and Attributable Risk Factors: An Epidemiological Analysis From 1990 to 2019, IJC Heart and Vasculature (2024)
3. Changes in Emergency Department Visits and Mortality During the Covid-19 Pandemic: A Retrospective Analysis of 956 Hospitals, Archives of Public Health (2024)
4. Cost-Utility Analysis of Pembrolizumab Compared to Other Alternative Immunotherapy and Chemotherapy Treatments for Patients With Advanced Melanoma in Iran, Expert Review of Pharmacoeconomics and Outcomes Research (2024)
5. Health-Related Quality of Life Measured Using the Eq-5D-3L: Iranian Population Norms, Expert Review of Pharmacoeconomics and Outcomes Research (2024)
6. Key Indicators for Monitoring the Efficiency of Iranian Health System: A Synthesized Design Study, Iranian Journal of Public Health (2024)
7. Non-Covid-19 Hospitalization and Mortality During the Covid-19 Pandemic in Iran: A Longitudinal Assessment of 41 Million People in 2019–2022, BMC Public Health (2024)
8. Patterns of Case Fatality and Hospitalization Duration Among Nearly 1 Million Hospitalized Covid-19 Patients Covered by Iran Health Insurance Organization (Ihio) Over Two Years of Pandemic: An Analysis of Associated Factors, PLoS ONE (2024)
9. Valuing the Sf-6Dv2 in the Capital of Iran Using a Discrete Choice Experiment With Duration, Quality of Life Research (2024)
10. A Cost-Effectiveness Analysis of Risk-Based Intervention for Prevention of Cardiovascular Diseases in Irapen Program: A Modeling Study, Frontiers in Public Health (2023)
11. A National Survey of Iranian General Population to Estimate a Value Set for the Eq-5D-5L, Quality of Life Research (2023)
12. Cost-Benefit Analysis of Stroke Rehabilitation in Iran, Expert Review of Pharmacoeconomics and Outcomes Research (2023)
13. Cost-Utility Analysis of Multiple Sclerosis Rehabilitation in Iran, Expert Review of Pharmacoeconomics and Outcomes Research (2023)
14. Cost-Utility Analysis of Palbociclib + Letrozole and Ribociclib + Letrozole Versus Letrozole Monotherapy in the First-Line Treatment of Metastatic Breast Cancer in Iran Using Partitioned Survival Model, Health Economics Review (2023)
15. Development of Attributes and Levels of Mental Health Insurance Services Using a Discrete Choice Experiment, Journal of Education and Health Promotion (2023)
16. Direct and Indirect Medical Costs of Bladder Cancer in Iran, Cost Effectiveness and Resource Allocation (2023)
17. Direct Costs of Hypertension Treatment in Iran, Iranian Journal of Public Health (2023)
18. Drug Prescription Patterns and Their Association With Mortality and Hospitalization Duration in Covid-19 Patients: Insights From Big Data, Frontiers in Public Health (2023)
19. Health-Related Quality of Life in Osteoporosis Patients With and Without Fractures in Tehran, Iran, Journal of Bone Metabolism (2023)
20. Is Palbociclib a Cost-Effective Strategy in the Second-Line Treatment of Metastatic Breast Cancer in Iran?, Expert Review of Pharmacoeconomics and Outcomes Research (2023)
21. Payment Systems for Dialysis and Their Effects: A Scoping Review, BMC Health Services Research (2023)
22. Utilization Trend of Parenteral Antidiabetic Drugs in Type 2 Diabetic Patients Covered by Iran Health Insurance Organization From 2011 to 2030, Iranian Journal of Public Health (2023)
23. A Cost-Effectiveness Modeling Study of Treatment Interventions for Stage I to Iii Esophageal Squamous Cell Carcinoma, Cost Effectiveness and Resource Allocation (2022)
24. Cost-Utility Analysis of Cryoballoon Ablation Versus Radiofrequency Ablation in the Treatment of Paroxysmal Atrial Fibrillation in Iran, PLoS ONE (2022)
25. Cost–Benefit Analysis of Human Papillomavirus Vaccine in Iran, Journal of Prevention (2022)
26. Economic Burden of Gynecological Cancers in Iran, Value in Health Regional Issues (2022)
27. Estimating the Cost of Student Training Using Activity-Based Costing (Abc) Method in the Department of Health Management and Economics at the School of Public Health, Tehran University of Medical Sciences, Journal of Payavard Salamat (2022)
28. Estimating the Prevalen Developing Country, Medical Journal of the Islamic Republic of Iran (2022)
29. Estimation and Predictors of Direct Hospitalisation Expenses and In-Hospital Mortality for Patients Who Had a Stroke in a Low-Middle Income Country: Evidence From a Nationwide Cross-Sectional Study in Iranian Hospitals, BMJ Open (2022)
30. Health Related Quality of Life in Adults With Asthma: A Systematic Review to Identify the Values of Eq-5D-5L Instrument, Journal of Asthma (2022)
31. Health-Related Quality of Life Among Adult Patients With Visual Impairments in Yazd, Iran, Journal of Education and Health Promotion (2022)
32. National Geographical Pattern of Covid-19 Hospitalization, Case Fatalities, and Associated Factors in Patients Covered by Iran Health Insurance Organization, BMC Public Health (2022)
33. Public Preferences and Willingness to Pay for a Covid-19 Vaccine in Iran: A Discrete Choice Experiment, PharmacoEconomics - Open (2022)
34. Public Preferences Regarding the Priority Setting Criteria of Health Interventions for Budget Allocation: Results of a Survey of Iranian Adults, BMC Public Health (2022)
35. The Burden of Cardiovascular Disease Attributable to Modifiable Risk Factors and Cost-Effectiveness Analysis of Irapen Program in the General Population of Iran, Medical Journal of the Islamic Republic of Iran (2022)
36. The Economic Burden of Esophageal Cancer in Iran, Indian Journal of Cancer (2022)
37. The Economic Burden of Osteoporosis in Iran in 2020, Osteoporosis International (2022)
38. The Lost Productivity Cost of Premature Mortality Owing to Cancers in Iran: Evidence From the Globocan 2012 to 2018 Estimates, Value in Health Regional Issues (2022)
39. An Assessment of Trends in the Iranian Pharmaceutical Market Following Domestic Production of Selected Medications (2007‒2017) and New Considerations for Health Policymakers, GaBI Journal (2021)
40. Application of Discrete Choice Experiments to Estimate Value of Life: A National Study Protocol in Iran, Cost Effectiveness and Resource Allocation (2021)
41. Assessment of Utility in Migraine: Mapping the Migraine-Specific Questionnaire to the Eq-5D-5L, Value in Health Regional Issues (2021)
42. Cost Per Daly Averted in Low, Middle- and High-Income Countries: Evidence From the Global Burden of Disease Study to Estimate the Cost-Effectiveness Thresholds, Cost Effectiveness and Resource Allocation (2021)
43. Cost-Effectiveness of a Population-Based Aaa Screening Program for Men Over 65 Years Old in Iran, Cost Effectiveness and Resource Allocation (2021)
44. Direct Costs of Common Osteoporotic Fractures (Hip, Vertebral and Forearm) in Iran, BMC Musculoskeletal Disorders (2021)
45. Economic Burden of Medication-Overuse Headache in Iran: Direct and Indirect Costs, Neurological Sciences (2021)
46. Mothers’ Preferences and Willingness-To-Pay for Human Papillomavirus Vaccines in Iran: A Discrete Choice Experiment Study, Preventive Medicine Reports (2021)
47. Safety and Effectiveness of Lung Cancer Screening Using Low-Dose Computed Tomography Scan in High-Risk Individuals: A Comprehensive Review, Health Technology Assessment in Action (2021)
48. Sarcopenia Screening Strategies in Older People: A Cost Effectiveness Analysis in Iran, BMC Public Health (2021)
49. The Impact of Common Chronic Conditions on Health-Related Quality of Life: A General Population Survey in Iran Using Eq-5D-5L, Cost Effectiveness and Resource Allocation (2021)
50. Diagnostic Accuracy of 64-Slice Computed Tomography Angiography in Patients With Chest Pain Vs. Spect in the Assessment of Significant Coronary Artery Disease: A Systematic Review and Meta-Analysis, Health Technology Assessment in Action (2020)
51. Erratum: Health-Related Quality of Life Measured Using the Eq-5D-5 L: Population Norms for the Capital of Iran (Health and Quality of Life Outcomes (2020) 18: 108 Doi: 10.1186/S12955-020-01365-5), Health and Quality of Life Outcomes (2020)
52. Estimation of Generalized Impact Fraction and Population Attributable Fraction of Hypertension Based on Jnc-Iv and 2017 Acc/Aha Guidelines for Cardiovascular Diseases Using Parametric G-Formula: Tehran Lipid and Glucose Study (Tlgs), Risk Management and Healthcare Policy (2020)
53. Health-Related Quality of Life Measured Using the Eq-5D-5 L: Population Norms for the Capital of Iran, Health and Quality of Life Outcomes (2020)
54. Economic Evaluation of Treatments for Patients With Esophageal Cancer: A Systematic Review, International Journal of Cancer Management (2019)
55. Estimation of Tehran's Particulate Matter 2.5 Micrometers or Less in Diameter (Pm2.5) Health Effects, Using Benmap-Ce, Iranian Journal of Health and Environment (2019)
56. Health Impact and Related Cost of Ambient Air Pollution in Tehran, Environmental Research (2019)
57. Epidemiology and Hospitalization Cost of Bladder Cancer in Kerman Province, Southeastern Iran, Iranian Journal of Public Health (2018)
58. Cost-Effectiveness of Screening Colonoscopy in Iranian High Risk Population, Archives of Iranian Medicine (2017)
59. Economic Burden of Colorectal Cancer in Iran in 2012, Medical Journal of the Islamic Republic of Iran (2017)
60. Estimation of the Prevalence and Direct Medical Costs of Chronic Myeloid Leukemia in the I.R. of Iran in the Era of Tyrosine Kinase Inhibitors, Asia-Pacific Journal of Clinical Oncology (2017)
61. Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-Making in Relation to New Cancer Drugs, International Journal of Health Policy and Management (2016)
62. Cost-Effectiveness of Different Cervical Screening Strategies in Islamic Republic of Iran: A Middle-Income Country With a Low Incidence Rate of Cervical Cancer, PLoS ONE (2016)
63. Determinants of Healthcare Expenditures in Iran: Evidence From a Time Series Analysis, Medical Journal of the Islamic Republic of Iran (2016)
64. Life and Health Satisfaction in the Adult Population of Iran, Epidemiology and health (2016)
65. The Economic Burden of Breast Cancer in Iran, Iranian Journal of Public Health (2015)
66. Years of Potential Life Lost and Productivity Costs Due to Premature Cancer-Related Mortality in Iran, Asian Pacific Journal of Cancer Prevention (2015)